China Recovers 118B Yuan in Medical Insurance Funds
China has recovered nearly 118.2 billion yuan (approximately $16.3 billion) in medical insurance funds during the “14th Five-Year Plan” period (2021-2025), according to the newly released 2025 National Medical Insurance Development Statistical Bulletin. The achievement highlights a sweeping crackdown on healthcare fraud in the world’s largest basic medical insurance system, which now covers over 1.33 billion people — approximately 95% of the population.
Context: A System Under Pressure
China’s medical insurance system has grown rapidly since the National Healthcare Security Administration (NHSA) was established in 2018. During the 14th Five-Year Plan period, cumulative medical insurance fund expenditure reached 13.67 trillion yuan, with an average annual growth rate of 7.40%. As the system expanded, so did the opportunities for fraud — ranging from hospitals offering free transportation to lure patients into unnecessary hospitalization, to organized rings reselling prescription drugs purchased through insurance.
According to People Daily, the NHSA processed 1,879,600 designated medical institutions through agreement-based handling nationwide over the five-year period, with medical insurance administration recovering 92.5 billion yuan of the total recovered funds.
Key Developments: Enforcement Intensifies
In 2025 alone, the system recovered 34.219 billion yuan, verified 1,626 medical institutions for fraud, and worked with public security authorities on 3,776 cases, resulting in 10,357 arrests. The NHSA also implemented a “driver’s license-style” points system for medical professionals, scoring 163,600 individuals, suspending 2,313, and permanently disqualifying 1,245 from medical insurance payments.
“The medical insurance department is focusing on the chronic problem of resold returned drugs, carrying out special operations nationwide,” said Gu Rong, Director of the NHSA Fund Supervision Department, as reported by People Daily. “In the first half of this year, medical insurance expenditure on 320 key monitored drugs prone to resale decreased by 19.2 billion yuan compared to 2025, a year-on-year decline of 20%.”
Huang Huabo, Deputy Director of the NHSA, noted at a press conference in March that “in the past five years, medical insurance departments at all levels have recovered approximately 120 billion yuan in medical insurance funds, with remarkable results in fund supervision,” as reported by Xinhua News Agency.
By the end of June 2026, the system had already recovered 16.35 billion yuan this year. Nationwide flight inspections — unannounced, cross-regional audits — covered 2,926 medical institutions across 227 cities, finding 1.16 billion yuan in suspected violations.
Analysis: Technology Transforms Enforcement
The shift toward AI-powered, data-driven supervision represents a fundamental change in enforcement capability. During the 14th Five-Year Plan period, intelligent medical insurance monitoring systems issued 249 million pre-event reminders, covering 419.38 billion yuan, and rejected 8.268 billion yuan during processing.
As the 21st Century Business Herald reported, the NHSA has built big data analysis models for detecting “abnormal hospitalizations,” “resale of medical insurance drugs,” and other violations. By the end of 2025, the unified medical insurance information platform had collected 112.768 billion drug traceability records, with over 5 million daily drug verification scans via the National Medical Insurance App.
A whistleblower reward program has also proven effective: 4,637 rewards were issued during the five-year period, totaling 8.5981 million yuan, with many major cases originating from public tips.
Legal Framework Matures
The regulatory landscape has evolved significantly. The Regulations on the Supervision and Administration of the Use of Medical Insurance Funds (implemented 2021) was supplemented by detailed Implementation Rules effective April 1, 2026, which specifically target inducement fraud and drug resale schemes. A dedicated Medical Insurance Law is currently under legislative review, having undergone first reading in June 2025 and second reading in April 2026.
Challenges Remain
Despite these achievements, the NHSA acknowledges that “fund leakage problems have not been completely eradicated” and fraud “occurs from time to time.” Fraud methods are becoming increasingly professionalized and concealed, while the growing diversity of fund users and lengthening fund flow chains add complexity to enforcement.
What’s Next
Looking ahead, the NHSA plans to further expand smart monitoring coverage — the pre-event reminder system’s access rate reached 71% by June 2026, up from 43.38% at the end of 2025. The pending Medical Insurance Law, once enacted, is expected to further strengthen enforcement capabilities by codifying flight inspections, drug traceability, and AI-powered monitoring into law.
As one industry expert told the 21st Century Business Herald, the core goal remains “to achieve medium- to long-term actuarial balance and ensure long-term stable operation” of the system that serves over a billion people.